On-demand sebetralstat speeds symptom relief in hereditary angioedema, clinical trial finds

For patients with type 1 or type 2 hereditary angioedema, sebetralstat provides faster times to beginning of symptom relief than placebo, according to a study published online May 31 in the New England Journal of Medicine to coincide with the annual congress of the European Academy of Allergy and Clinical Immunology, held from May 31 to June 3 in Valencia, Spain. Marc A. Riedl, M.D., from the University of California at San Diego in La Jolla, and colleagues conducted a Phase III trial involving participants aged 12 years or older Read More

Related posts:

  1. Trained peers are as effective as clinical social workers in reducing opioid overdose, new trial finds
  2. AI model to improve clinical trial recruitment for eye disease
  3. Clinical trial investigates using electronic alerts to help control blood pressure
  4. Breakthrough brain recording device receives FDA approval for a clinical trial
  5. First-of-its-kind clinical trial eliminates or shrinks melanoma tumors in 70% of patients
  6. Clinical trial shows promising results in a two-drug combination that curbs methamphetamine use
  7. Researchers say AI accurately screens heart failure patients for clinical trial eligibility
  8. Clinical trial could lead to new ‘gold standard’ test for prostate cancer detection

Leave a Reply

Your email address will not be published. Required fields are marked *